# Yubo International Biotech Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Yubo International Biotech Ltd). ## Overview Yubo International Biotech Ltd is a U.S.-listed holding company whose operating business is conducted in China through Yubo International Biotech (Beijing) Limited and related contractual arrangements. The business focuses on endometrial stem cell research and application, and markets a mix of healthcare products and stem cell-related services under the VIVCELL brand. ## Products & services • Endometrial stem cell research and application • Respiratory system healthcare products • Skincare and hair care products • Healthy beverages • Male and female personal care products • Cell testing services • Health management consulting services - **Stem cell research and services** (20%) — Research, testing, and consulting services centered on endometrial stem cells. - **Respiratory healthcare products** (20%) — Consumer healthcare products positioned for respiratory wellness and related care. - **Skincare and hair care products** (20%) — Beauty and personal care products sold under the VIVCELL brand. - **Healthy beverages** (15%) — Functional beverage products marketed as part of the wellness portfolio. - **Personal care products** (15%) — Male and female personal care products tied to the company’s consumer health offering. - **Health management consulting** (10%) — Consulting services related to health management and cell-related wellness. - Endometrial stem cell research and application - Respiratory system healthcare products - Skincare and hair care products - Healthy beverages - Male and female personal care products - Cell testing services - Health management consulting services ## Customers The company sells to a small number of customers, with historical revenue concentrated in a limited customer base in China. Its offerings appear to serve both consumer wellness buyers and customers seeking cell testing or health management services. The concentration disclosed in filings suggests that a few counterparties can materially affect near-term sales. - **Consumer wellness customers** (primary) — Buy branded healthcare, skincare, hair care, beverage, and personal care products for everyday use. - **Stem cell service clients** (secondary) — Use cell testing and health management consulting tied to the company’s stem cell platform. - **Wholesale/distribution customers** (primary) — Purchase product inventory or act as channel partners for the VIVCELL brand in China. - Consumer wellness buyers purchasing skincare, hair care, and beverages - Customers seeking respiratory and personal care products - Clients using cell testing services and health management consulting - A limited number of wholesale or distribution customers in China - Revenue can be highly concentrated in one or a few customers ## Geography Yubo International Biotech is a U.S. holding company, but its operating activities are centered in Beijing, China through a VIE structure. The filings indicate that day-to-day business is conducted in China, making the company dependent on Chinese licenses, approvals, and operating conditions. This structure creates a clear geographic split between the listed parent and the operating business. - **China** (100%) — Operating business and customer base are centered in China. - U.S.-listed holding company with operating business in China - Principal executive offices are in Beijing, China - Day-to-day operations are conducted through Yubo Beijing - Chinese licenses and approvals are required to operate - Geographic exposure is concentrated in mainland China ## Strategy The company’s strategy is centered on building its stem cell platform while commercializing a broader VIVCELL-branded wellness portfolio. It also relies on maintaining the licenses, approvals, and contractual structure needed to operate in China through a VIE. Customer concentration and product breadth suggest a need to broaden the commercial base while keeping the core technology narrative intact. - **Advance the stem cell platform** (medium-term) — The company’s differentiation depends on its endometrial stem cell research and related services. - **Commercialize consumer wellness products** (short-term) — Product sales provide a broader market beyond specialized stem cell services. - **Preserve China operating access** (short-term) — The business depends on PRC licenses, approvals, and contractual arrangements with the VIE. - Develop endometrial stem cell research and application capabilities - Commercialize VIVCELL-branded wellness and personal care products - Expand service offerings such as cell testing and consulting - Maintain required PRC licenses and approvals for operations - Reduce dependence on a small number of customers ## Risks The company faces concentration risk because historical revenue has come from a limited number of customers, and recent periods disclosed no sales. Its China-based operating model also exposes it to PRC regulatory, licensing, and VIE-structure risks, while the consumer health and biotech mix adds product, compliance, and execution risk. As a small operating platform, it is also vulnerable to demand volatility and dependence on a narrow set of products and counterparties. - **Customer concentration** [high] — Historical revenue has been generated from a limited number of customers, increasing dependence on a few buyers. - **Operating and regulatory risk in China** [high] — The business requires PRC licenses and approvals to operate and is subject to local regulatory oversight. - **VIE structure and contractual control risk** [high] — The listed parent does not directly own the PRC operating company, so control depends on contractual arrangements. - **Product and compliance risk** [medium] — Healthcare, personal care, and food-related products can face quality, labeling, and regulatory compliance issues. - Heavy customer concentration can cause large swings in revenue - No sales in recent quarters highlight demand and execution risk - China operating model depends on PRC licenses and approvals - VIE structure creates legal and control uncertainty - Consumer health and biotech products face regulatory scrutiny ## Accounting The company’s filings highlight judgment-heavy areas such as fair value measurements, earnings per share, accrued expenses, financing operations, and contingencies. Because the business operates through a VIE and has limited recent sales, investors should also watch how related-party arrangements, estimates, and going-concern-style assumptions affect reported results and comparability. - **Fair value measurements** — Valuation assumptions can change earnings and balance sheet values - **Earnings per share** — Dilution and share structure may distort per-share comparability - **Accrued expenses and contingencies** — Expense recognition may shift between periods - **VIE consolidation and related-party arrangements** — Consolidation judgments affect what assets, liabilities, and revenue are reported - Fair value measurements require valuation judgments - EPS can be affected by the holding-company structure - Accrued expenses and contingencies rely on management estimates - VIE and contractual arrangements can complicate consolidation - Low or absent sales make quarterly comparisons volatile --- *Last updated: 2026-04-29T05:11:21.434973+00:00*